Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02500199 |
|
Recruitment Status : Unknown
Verified January 2021 by Hengrui Therapeutics, Inc..
Recruitment status was: Active, not recruiting
First Posted : July 16, 2015
Last Update Posted : February 1, 2021
|
Sponsor:
Hengrui Therapeutics, Inc.
Information provided by (Responsible Party):
Hengrui Therapeutics, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | May 2021 |
| Estimated Study Completion Date : | June 2021 |